Med Tech Business and Auryon/NanoKnife Products Drive Growth

  • AngioDynamics shares rise 22% after beating 4Q sales expectations
  • Quarterly sales reach $71 million, up from $91.1 million last year
  • Med Tech business sees double-digit growth with strong revenue from Auryon and NanoKnife products
  • Fiscal 2025 sales forecasted between $282 million to $288 million

AngioDynamics, a medical technology company, reported a 22% increase in its share price after beating fourth-quarter sales expectations. The company’s shares reached $7.22 following the announcement of $71 million in quarterly sales, up from $91.1 million in the same period last year. The growth was driven by their Med Tech business, with strong revenue contributions from Auryon and NanoKnife products. For fiscal 2025, AngioDynamics anticipates sales between $282 million to $288 million.

Factuality Level: 9
Factuality Justification: The article provides accurate and objective information about the company’s financial performance, including sales figures, stock price changes, and expectations for future sales and losses. It also includes relevant details about specific products contributing to revenue growth.
Noise Level: 6
Noise Justification: The article provides relevant information about the company’s financial performance and sales figures but lacks in-depth analysis or exploration of long-term trends or consequences of decisions. It also does not offer actionable insights or new knowledge for readers.
Public Companies: AngioDynamics (Unknown)
Key People:

Financial Relevance: Yes
Financial Markets Impacted: AngioDynamics stock
Financial Rating Justification: The article discusses the company’s financial performance, including sales and losses, as well as its expectations for future sales and adjusted loss. This directly impacts the company’s stock price in the financial markets.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the article.

Reported publicly: www.marketwatch.com